key: cord-0763929-xz037dfa
authors: Kumar, Pramod; Kulkarni, Anand; Sharma, Mithun; Nagaraja Rao, Padaki
title: Repurposing Hepatitis C Direct -acting antivirals against COVID-19
date: 2020-10-10
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2020.10.001
sha: c65cec2124aec3f74f7be4bfb31fbe26c205ffeb
doc_id: 763929
cord_uid: xz037dfa

nan

Number of tables -1

Key words-Hepatitis C, Sofosbuvir, Daclatasvir, SARS-CoV-2

To the Editor:

The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intervening early in the disease course by antivirals delays progression and improves clinical outcomes. 1 The pandemic has led to the rapid repurposing of many clinically approved drugs for other diseases.

Direct-acting antivirals (DAAs) changed the entire landscape of hepatitis C (HCV) treatment.

(2) There has been considerable interest with DAAs like sofosbuvir, daclatasvir, and 

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Direct-acting antiviral treatment for hepatitis C

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro ) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2